Farm trial shows controlling respiratory disease at weaning pays for itself five times over

摘要

Results from a new farm trial carried out by Elanco show an average return on investment of 5:1 from the use of Pulmotil at weaning to reduce the impact of complex respiratory disease. Respiratory disease remains one of the major disease issues on most pig units, being associated with reduced performance and increased mortality. New research into Pulmotil's mode of action indicated it could play a role in the cost effective control of respiratory disease when used immediately after weaning.